Autoinflammation in 2010: expanding clinical spectrum and broadening therapeutic horizons

Nat Rev Rheumatol. 2011 Feb;7(2):82-4. doi: 10.1038/nrrheum.2010.229.

Abstract

In 2010, important research into the systemic autoinflammatory diseases has confirmed and extended the role of IL-1 inhibition in hereditary autoinflammatory disorders, demonstrated a novel treatment for a dangerous complication, and expanded the spectrum of systemic autoinflammatory diseases while further implicating autoinflammation in the pathophysiology of the metabolic syndrome.

Publication types

  • Review

MeSH terms

  • Amyloidosis / drug therapy
  • Amyloidosis / etiology
  • Animals
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use*
  • Atherosclerosis / etiology
  • Hereditary Autoinflammatory Diseases / complications
  • Hereditary Autoinflammatory Diseases / drug therapy*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / pharmacology
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Interleukin-1 / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1